secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eloxx Pharmaceuticals, Inc. (ELOX)
CIK:        0001035354
Form:       8-K
Filed at:   2023-04-03T23:59:59+00:00
Accession:  0001104659-23-040585
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eloxx reports Q4 net loss $6.3M, cash $19.2M; Phase 2 Alport study ongoing, IND filed for ZKN-013
--------------------------------------------------------------------------------

- Net loss $6.3M ($2.92/share) vs $12.1M loss in Q4 2021; R&D and G&A expenses decreased YoY.
- Unrestricted cash $19.2M at Dec 31, 2022; amended Hercules loan repaid $7.5M; cash runway into Q3 2023.
- Three patients dosed in Phase 2 ELX-02 for Alport; initial proteinuria reduction observed; topline data H1 2023.
- IND filed for ZKN-013 for RDEB; preclinical read-through up to 18-fold increase in COL VII protein.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923040585/0001104659-23-040585-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1035354/000110465923040585/tm2311039d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-040585

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer